Fanny Billiot

Institut Gustave Roussy — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index941citations40works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(16), Angiogenesis and VEGF in Cancer(14), Cancer Cells and Metastasis(12), Lung Cancer Treatments and Mutations(11), Metastasis and carcinoma case studies(6)

Publications40 total

Supplementary Video 2 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Data from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 3 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Table 1, Figures 1-8, Movie Legends 1-4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Data from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 3 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 1 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Table 1, Figures 1-8, Movie Legends 1-4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 1 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 2 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Video 4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
2023Open Access
Supplementary Figure 1 from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
Data from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Figure 1 from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Tables and Legends from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Tables and Legends from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
Data from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients
2023Open Access
An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer
European Urology Oncology·2019· 38 citedOpen Access
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
Annals of Oncology·2017· 90 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Françoise Farace(38), Jean‐Charles Soria(35), Philippe Vielh(26), Emma Pailler(20), Benjamin Besse(17), Marianne Oulhen(16), David Planchard(15), Mélissa Taylor(15), Virginie Marty(15), Corinne Laplace‐Builhé(15), Elodie Tournay(14), Valérie Rouffiac(13), Patrick Cohen(13), Paule Opolon(13), Fawzia Louache(13), Gilles Vassal(13), Colin R. Lindsay(12), Maud Ngo‐Camus(11), Jordi Remón(11), Vincent Faugeroux(8)